Why Is ImmunityBio (IBRX) Stock Down -23% Today?
Key Takeaways
- IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23.
- The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
- The stock's outsized year-to-date gain — exceeding 300% entering this week — has left it exposed to rapid reversals, particularly among retail and short-term momentum traders.
- Persistent net losses, elevated cash burn, and execution risks around ANKTIVA commercialization continue to weigh on longer-term sentiment.
- Broader biotech sector weakness has compounded the selling pressure on March 24.
- Traders are watching the $7.77 key support level; a breakdown below that level could open a test of $5.94.
Opening Summary
ImmunityBio, Inc. (IBRX) is a Culver City, California-based clinical-stage immunotherapy company whose lead commercial product, ANKTIVA (N-803), is approved in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company has also been advancing ANKTIVA across additional indications, including BCG-naïve NMIBC and metastatic non-small cell lung cancer. Shares closed Monday's session at $9.40 — up more than 11% on the day — but have reversed sharply in Tuesday's session, declining approximately 23% to trade near $7.24 as of mid-session. The move erases all of the prior day's gains and then some, in what appears to be a rapid unwind of momentum-driven positioning after an extended multi-week rally.
Profit-Taking After a Parabolic Run
The most immediate driver of Tuesday's decline is aggressive profit-taking following one of the most dramatic rallies in the small-cap biotech space this year. IBRX entered this week up more than 300% year-to-date, having risen from under $2.00 at the start of 2026 to a peak above $12.40 in late February. Monday's additional 11%+ gain pushed the stock back toward recent highs, a level that has repeatedly attracted heavy selling. Retail-heavy momentum stocks with this kind of vertical appreciation routinely experience sharp, single-day reversals as traders who bought earlier in the year lock in gains — and that pattern is playing out clearly in Tuesday's session.
Valuation Concerns and Persistent Losses
Despite ANKTIVA's commercial ramp, investor concerns about ImmunityBio's fundamental profile have not abated. The company reported full-year 2025 revenues of approximately $113 million — representing impressive year-over-year growth of roughly 700% — but remained deeply unprofitable, posting a net loss attributable to shareholders of $351.4 million, which narrowed by approximately 15% from the prior year. At Monday's closing price, IBRX was trading at roughly 33 times trailing annual sales, a premium that assumes flawless execution of ANKTIVA's global rollout, label expansion into BCG-naïve NMIBC, and a meaningful reduction in cash burn. Any hesitation in the market's willingness to pay that multiple — particularly following a session in which shares had already surged — creates the conditions for an outsized drawdown.
Pipeline and Regulatory Overhang
Regulatory uncertainty is also contributing to Tuesday's risk-off sentiment around IBRX. On March 9, the company resubmitted a supplemental Biologics License Application (sBLA) to the FDA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary-only disease, following the agency's request for additional efficacy and long-term follow-up data. While ImmunityBio says no new clinical trials were requested, the resubmission process introduces a new FDA review timeline and a degree of regulatory uncertainty that investors are pricing in. Additionally, the company has flagged a "terrible" shortage of BCG — the standard bladder cancer therapy with which ANKTIVA is combined — with Merck remaining the sole global supplier, a supply-chain constraint that could limit near-term uptake.
Sector and Market Context
Tuesday's IBRX decline is also occurring against a backdrop of broader pressure on high-beta biotech names. Speculative growth stocks, particularly those with elevated short interest, are highly sensitive to shifts in overall market risk appetite. IBRX has carried significant short interest throughout its 2026 rally, meaning that while short covering has periodically amplified upside moves, the reverse is equally true — any turn in sentiment can accelerate selling as leveraged long positions unwind. Volume in Tuesday's session appears elevated relative to the 20-day average, consistent with a distribution day rather than ordinary retracement. Key technical support sits at $7.77; a sustained break below that level would represent a significant deterioration in the near-term chart structure.
Trending AI Robots
For traders navigating volatile stocks like IBRX, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers across equities, ETFs, and crypto — but only those demonstrating the strongest real-time performance metrics are featured in the Trending section. Each bot varies by strategy type, holding period, traded symbols, and risk profile, allowing traders to identify approaches aligned with their own goals. Whether the objective is momentum trading, mean-reversion, or sector rotation, the Trending AI Robots section serves as a live leaderboard of what is working right now. Traders looking to complement their own analysis with systematic, data-driven tools are encouraged to explore what Tickeron's AI ecosystem has to offer.
What Comes Next for IBRX
Looking ahead, several milestones will shape IBRX's trajectory in the coming months. The most closely watched event is the FDA's review of the resubmitted sBLA for ANKTIVA in BCG-unresponsive papillary NMIBC; a response timeline from the agency will be a defining near-term catalyst. On the clinical front, the company expects to file a BLA for ANKTIVA in BCG-naïve NMIBC by Q4 2026, underpinned by statistically significant interim data from the QUILT 2.005 trial showing a 9-month complete response rate of 84% versus 52% for BCG alone. International expansion — including the Saudi Arabia launch and the recently granted Macau SAR approval — represents incremental revenue opportunities. However, cash runway, the pace of ANKTIVA adoption in community urology settings, and the ongoing BCG supply shortage remain key risks that analysts and institutional investors will continue to monitor closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
IBRX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for IBRX moved out of overbought territory on August 21, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 48 similar instances where the indicator exited the overbought zone. In of the 48 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IBRX entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on IBRX as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IBRX just turned positive on August 07, 2026. Looking at past instances where IBRX's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
IBRX moved above its 50-day moving average on August 17, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IBRX crossed bullishly above the 50-day moving average on August 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (47.170) is also within normal values, averaging (444.692).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement